About Afinitor for Advanced Renal Cell Carcinoma (RCC)

 

DEVELOPING A TREATMENT PLAN

AFINITOR $25 CO-PAY CARD

IMAGE: AFINITOR Universal CO-PAY CARD
 
 
 

AFINITOR After Nexavar® (sorafenib)

Taking AFINITOR after treatment with Nexavar

A time may come in your journey when the test results show that your cancer is active and growing again. Do not get discouraged if your doctor tells you that you need to switch medications. This is common, and there are many alternative treatment options available to you.

Should you need to revise your treatment plan, you should keep in mind that the second medicine you take on your journey may depend on which medicine you have already taken.

If you have taken Nexavar and needed to stop because your cancer has progressed, AFINITOR might be a second-line treatment option for you.

AFINITOR Journey: A downloadable tool designed to help you understand one of the steps on this journey that may be right for you.

Download now:

English | Espaņol | Русский | 中文

AFINITOR: An oral second-line therapy with a different mechanism of action

AFINITOR is an oral tablet that is taken once daily, consistently with or consistently without food. You may take AFINITOR at home or any other place that is convenient for you. This may eliminate the need to receive treatment in your doctor's office. AFINITOR should be taken at the same time every day.

AFINITOR may slow the growth and spread of kidney cancer. It can restrict cancer cells from getting the nutrition they need to grow. It may slow blood vessels from growing and supplying the tumor with blood.

Important Safety Information

Lung or Breathing Problems: In some patients, lung or breathing problems may be severe and can even lead to death. Patients should tell their health care provider right away if they have any of these symptoms: new or worsening cough, shortness of breath, chest pain, difficulty breathing, or wheezing.

Please see additional Important Safety Information at the bottom of this page.

Please see full Prescribing Information for AFINITOR, including Patient Information.

To learn more about how AFINITOR works, click here.

AFINITOR clinical trial results

A clinical trial compared 277 patients who received AFINITOR plus best supportive care to 139 patients who received sugar tablets (placebo) plus best supportive care. Seventy-four percent of patients received prior sunitinib or sorafenib, and 26% received both sequentially. This study showed that AFINITOR doubled the amount of time patients lived without their tumors growing or spreading (progression-free survival). 4.9 months with AFINITOR plus best supportive care vs 1.9 months with placebo plus best supportive care (P<0.0001)

Important Safety Information

Lung or Breathing Problems: In some patients, lung or breathing problems may be severe, and can even lead to death. Patients should tell their health care provider right away if they have any of these symptoms: new or worsening cough, shortness of breath, chest pain, difficulty breathing, or wheezing.

Please see additional Important Safety Information at the bottom of this page.

Please see full Prescribing Information for AFINITOR including Patient Information.

AFINITOR insurance support for eligible patients

Patient Assistance NOW Oncology is a free program offered to eligible AFINITOR patients. This program helps to determine your eligibility for insurance coverage, and offers co-pay support and prescription and pharmacy assistance.Click here to find out more about Patient Assistance NOW Oncology.

 

ADVANCED RENAL CELL CARCINOMA (aRCC)

AFINITOR® (everolimus) Tablets is a prescription medicine used to treat adults with advanced kidney cancer (renal cell carcinoma or RCC) when certain other medicines (ie, Sutent® [sunitinib] or Nexavar® [sorafenib]) have not worked.

Important Safety Information

AFINITOR can cause serious side effects, including lung or breathing problems, infections, and kidney failure, which can lead to death. Patients who take an angiotensin-converting enzyme (ACE) inhibitor medicine during treatment with AFINITOR are at a possible increased risk for a type of allergic reaction called angioedema. AFINITOR can cause incisions to heal slowly or not heal well. Mouth ulcers and mouth sores are common side effects, occurring in up to 78% of patients taking AFINITOR. AFINITOR can affect blood cell counts, kidney and liver function, and blood sugar and cholesterol levels. Regular blood tests should be performed before starting AFINITOR and as needed during treatment to check blood cell count, kidney and liver function, and blood sugar and cholesterol levels.

Please see additional

Important Safety Information.

Please see full Prescribing Information for AFINITOR, including Patient Information.

 
 

Important Safety Information

Patients should not take AFINITOR® (everolimus) Tablets if they are allergic to AFINITOR or to any of its ingredients. Patients should tell their health care provider before taking AFINITOR if they are allergic to sirolimus (Rapamune®) or temsirolimus (Torisel®).

AFINITOR can cause serious side effects that can even lead to death. If patients experience these side effects, they may need to stop taking AFINITOR for a while or use a lower dose. Patients should follow their health care provider's instructions. Serious side effects include:

Lung or Breathing Problems: In some patients, lung or breathing problems may be severe and can even lead to death. Patients should tell their health care provider right away if they have any of these symptoms: new or worsening cough, shortness of breath, chest pain, difficulty breathing, or wheezing.

Infections: AFINITOR may make patients more likely to develop an infection, such as pneumonia, or a bacterial, fungal, or viral infection. Viral infections may include reactivation of hepatitis B in people who have had hepatitis B in the past. In some people these infections may be severe and can even lead to death. Patients may need to be treated as soon as possible. Patients should tell their health care provider right away if they have a temperature of 100.5°F or above, have chills, or do not feel well. Symptoms of hepatitis B or infection may include the following: fever, chills, skin rash, joint pain and inflammation, tiredness, loss of appetite, nausea, pale stools or dark urine, yellowing of the skin, or pain in the upper right side of the stomach.

Angioedema: Patients who take an angiotensin-converting enzyme (ACE) inhibitor medicine during treatment with AFINITOR are at a possible increased risk for a type of allergic reaction called angioedema. Talk with your health care provider before taking AFINITOR if you are not sure if you take an ACE inhibitor medicine. Get medical help right away if you have trouble breathing or develop swelling of your tongue, mouth, or throat during treatment with AFINITOR.

Kidney Failure: Patients taking AFINITOR may develop kidney failure. In some people this may be severe and can even lead to death. Patients should have tests to check their kidney function before and during their treatment with AFINITOR.

Delayed Wound Healing: AFINITOR can cause incisions to heal slowly or not heal well. Call your health care provider right away if your incision is red, warm, or painful; if you have blood, fluid, or pus in your incision; if your incision opens up; or if your incision swells.

Before taking AFINITOR, tell your health care provider about all your medical conditions, including if you:

Tell your health care provider about all of the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Using AFINITOR with certain other medicines can cause serious side effects. Keep a list of medicines you take and show it to your health care provider when you get a new medicine. Especially tell your health care provider if you take St John's wort (Hypericum perforatum), medicines that weaken your immune system (your body's ability to fight infections and other problems), or medicines for:

  • Fungal infections
  • Bacterial infections
  • Tuberculosis
  • Seizures
  • HIV-AIDS
  • Heart conditions or high blood pressure
 

If you are taking any medicines for the conditions listed above, your health care provider might need to prescribe a different medicine or your dose of AFINITOR may need to be changed. Tell your health care provider before you start taking any new medicine.

Common Side Effects: Common side effects include mouth ulcers. AFINITOR can cause mouth ulcers and sores. Tell your health care provider if you have pain, discomfort, or open sores in your mouth. Your health care provider may tell you to use a special mouthwash or gel that does not contain alcohol, hydrogen peroxide, iodine, or thyme.

Other common side effects include:

  • Infections
  • Feeling weak or tired
  • Cough, shortness of breath
  • Diarrhea and constipation
  • Rash, dry skin, and itching
  • Nausea and vomiting
  • Fever
  • Loss of appetite, weight loss
  • Swelling of arms, hands, feet, ankles, face, or other parts of the body
  • Abnormal taste
  • Dry mouth
  • Inflammation of the lining of the digestive system
  • Headache
  • Nose bleeds
  • Pain in arms and legs, mouth and throat, back or joints
  • High blood glucose
  • High blood pressure
  • Difficulty sleeping
  • Hair loss
  • Muscle spasms
  • Feeling dizzy
  • Nail disorders
 

Other side effects that may occur with AFINITOR:

Tell your health care provider if you have any side effect that bothers you or does not go away.

These are not all the possible side effects of AFINITOR. For more information, ask your health care provider or pharmacist. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information for AFINITOR, including Patient Information.

The brands listed are the trademarks or register marks of their respective owners and are not trademarks or register marks of Novartis.

Indication

Advanced Renal Cell Carcinoma (RCC)

AFINITOR is a prescription medicine used to treat adults with advanced kidney cancer (renal cell carcinoma or RCC) when certain other medicines (ie, Sutent® [sunitinib] or Nexavar® [sorafenib]) have not worked.

The brands listed are the trademarks or registered trademarks of their respective owners and are not trademarks or register marks of Novartis.